EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Overcoming barriers in cancer therapy with oncolytic adenoviruses: Engineering strategies and clinical perspectives

Rohit Sharma, Rahul Sharma, Kamal Dua, Gaurav Gupta, Dinesh Kumar Chellappan, Sachin Kumar Singh, Thakur Gurjeet Singh, Poonam Negi

Pathology - Research and Practice · 2026

DOI: 10.1016/j.prp.2026.156351 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2026. Verfasst von Rohit Sharma und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Neoplasms, Oncolytic Viruses, Adenoviridae. Die Arbeit nennt 122 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic adenoviruses (OADVs) have emerged as promising therapeutics for cancer treatment, offering tumour-selective replication and potent antitumor effects. These genetically engineered viruses infect and lyse cancer cells while simultaneously activating antitumor immunity. OADV can be engineered with therapeutic genes and tumour-specific promoters, further enhancing their specificity and efficacy. Various researchers have explored the use of OADV in cancer treatment, integrating direct oncolysis with immune activation, hence revealing promising therapeutic effects in preclinical studies. This review provides comprehensive insights into the mechanism of OADV engineering with tumor-specific promoters and therapeutic payloads, emphasizing advances in vector design that enhance specificity and efficacy. Key evidence from preclinical and clinical studies across lungs, pancreatic, hepatic, breast, renal, and brain cancers is highlighted, demonstrating the translational impact of OADV therapy. The synergistic potential of OADVs in combination regimens, including chemotherapy, immunotherapy, and gene therapy, is critically appraised. The review further examines central hurdles such as antiviral immunity, tumor microenvironment complexity, and delivery challenges, discussing innovative strategies like genetic modulation and nanoparticle carriers to overcome these barriers. Through integrating direct oncolysis and immune modulation, OADVs offer a multifaceted approach for the treatment of resistant and heterogeneous malignancies. The future of OADV therapy requires continued refinement in vector engineering, personalized delivery systems, and multidisciplinary research, positioning OADVs as pivotal agents for enhancing patient outcomes and quality of life in cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyNeoplasmsOncolytic VirusesAdenoviridaeHumansAnimalsGenetic TherapyGenetic EngineeringImmunotherapyGenetic Vectors

Stichwörter der Autor:innen

Antitumor immune responseCancer immunotherapyGene–virus combination therapyOncolytic AdenovirusTumor microenvironmentViral vector delivery

Autor:innen und Institutionen

  • Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab 140401, India.
  • Department of Pharmaceutics, School of Pharmacy, Abhilashi University, Chail Chowk, Mandi, Himachal Pradesh 175028, India.
  • Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia; Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology…
  • Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India; Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman, United Arab Emirates.
  • Department of Life Sciences, School of Pharmacy, International Medical University (IMU), Bukit Jalil, Kuala Lumpur 57000, Malaysia.
  • School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India.

Zitieren

APA

Sharma, R., Sharma, R., Dua, K., Gupta, G., Chellappan, D. K., Singh, S. K., Singh, T. G., & Negi, P. (2026). Overcoming barriers in cancer therapy with oncolytic adenoviruses: Engineering strategies and clinical perspectives. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2026.156351

Vancouver

Sharma R, Sharma R, Dua K, Gupta G, Chellappan DK, Singh SK, et al. Overcoming barriers in cancer therapy with oncolytic adenoviruses: Engineering strategies and clinical perspectives. Pathology - Research and Practice. 2026. doi:10.1016/j.prp.2026.156351

BibTeX
@article{Sharma2026,
  author = {Sharma, Rohit and Sharma, Rahul and Dua, Kamal and Gupta, Gaurav and Chellappan, Dinesh Kumar and Singh, Sachin Kumar and Singh, Thakur Gurjeet and Negi, Poonam},
  title = {Overcoming barriers in cancer therapy with oncolytic adenoviruses: Engineering strategies and clinical perspectives},
  journal = {Pathology - Research and Practice},
  year = {2026},
  doi = {10.1016/j.prp.2026.156351}
}
Kostenlos starten →